A case of multiple myeloma in a poultry worker

Conclusions This case report suggests that poultry workers may be exposed to high levels of various hazardous chemicals including pesticides and/or organic solvents. Numerous previous studies have suggested an association between multiple myeloma and exposure to agricultural chemicals; thus, multiple myeloma in this patient might have resulted from the prolonged, high exposure to these chemicals.
Source: Annals of Occupational and Environmental Medicine - Category: Occupational Health Source Type: research

Related Links:

ConclusionThe e-TEP-RS technique for large, complex, midline, ventral abdominal hernias can be used with excellent results and acceptable morbidity. This technique is technically challenging and should be mastered in relatively smaller ventral hernias to achieve good results before attempting it in larger, complex ones.
Source: Hernia - Category: Sports Medicine Source Type: research
This study evaluates the effectiveness of two postoperative analgesia modalities: epidural cat heter and surgeon-performed TAP-block following VHR performed with transversus abdominis release (TAR).MethodsA retrospective analysis was performed on data prospectively collected between 2012 and 2019. All patients undergoing open VHR with TAR performed by a single surgeon were identified. Parastomal hernia repairs and any patients receiving ultrasound-guided TAP blocks or paraspinal blocks were excluded. Primary outcome was length of stay (LOS) with secondary outcomes including pain scores, opioid requirements, and 30-day morb...
Source: Hernia - Category: Sports Medicine Source Type: research
Here are the results of the poll. Is It Time To Give Up On The DOH/NETHA/ADHA Experiment Of Federal Government Involvement In Digital Health In Australia? Yes - It Has Been Long Enough 53% (43) No - They Need More Time To Get It Right 35% (28) I Have No Idea 12% (10) Total votes: 81 A small majority want to see the pain of the last decade stop while many more that usual are really confused. Quite a few wanted to be patient for a while longer - maybe worried about their jobs? Any insights on the poll are welcome, as a comment, as usual! A good number of votes with a clear outcome!  A very large 10 of 81 who answer...
Source: Australian Health Information Technology - Category: Information Technology Authors: Source Type: blogs
CONCLUSIONS: Practice-level adoption of PES for patients with musculoskeletal problems was generally not associated with total spending. PES, however, may steer patients toward evidence-based treatments. Opportunities for overall spending reduction exist as indicated by the variation in the subcomponents of total spending by PES adoption.PMID:34836905 | DOI:10.1136/bmjopen-2021-053121
Source: Pain Physician - Category: Anesthesiology Authors: Source Type: research
CONCLUSIONS: This study supports the use of transparent face masks by health care professionals in an orthopedic department, particularly by nurses. In addition, this study supports the assumption of problems involving the reliability of VAS.PMID:34836821 | DOI:10.1016/j.pmn.2021.09.005
Source: Pain Physician - Category: Anesthesiology Authors: Source Type: research
RARITAN, N.J., May 26, 2021 – The Janssen Pharmaceutical Companies of Johnson &Johnson today announced updated results from the Phase 3 ANDROMEDA study, which evaluated DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare blood cell disorder associated with the deterioration of vital organs, most notably the heart, kidneys and liver.[1] Longer-term results from a median follow-up of 20.3 months showed rates of hematologic complete response (hemCR) remained significantly higher in patients treated with DARZALEX FASPRO®...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to the...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Our Company Source Type: news
RARITAN, N.J., November 5, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today more than 35 company-sponsored studies, including 10 oral presentations, will be featured at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition taking place virtually December 5-8, 2020.In multiple myeloma, highlights include Phase 1b/2 results for the B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor T-cell (CAR-T) therapy ciltacabtagene autoleucel (cilta-cel); new and updated data for the anti-CD38 monoclonal antibody DARZALEX® (daratumumab) and the subcutaneo...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
RARITAN, NJ, June 13, 2020 – The Janssen Pharmaceutical Companies of Johnson &Johnson announced today results from the first randomized Phase 3 study investigating subcutaneous daratumumab[i] in the treatment of patients with newly diagnosed light chain (AL) amyloidosis, a rare and potentially fatal disease.[1],[2] The data demonstrated subcutaneous daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) resulted in a higher hematologic complete response rate (CR), (53 percent vs. 18 percent [P
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
By Stacy SimonThe US Food and Drug Administration (FDA) has approved the third drug this year for treating multiple myeloma, a type of cancer that starts in plasma cells. Ninlaro (ixazomib) is a targeted therapy drug approved to be given in combination with two other drugs – lenalidomide and dexamethasone. This combination is the first all-oral regimen for treating multiple myeloma. It’s intended for people who have received at least one previous treatment.The FDA based its approval on a clinical trial of 722 people with multiple myeloma that didn’t get better with treatment, or came back after treatment....
Source: American Cancer Society :: News and Features - Category: Cancer & Oncology Tags: Multiple Myeloma Source Type: news
More News: Bone Marrow Aspiration and Biopsy | Chemistry | Environmental Health | Myeloma | Occupational Health | Pain | Rare Diseases | Study